Semaglutide is part of a group of medications called GLP-1 receptor agonists
Reflections injectors were awarded by Allergan (the makers of Kybella and other injectables) and Merz (makers of Xeomin, Radiesse, and Belotero) for their expert skills as injectors
The FDA determined the tirzepatide shortage resolved in late 2024 and the semaglutide shortage resolved in February 2025, and it set enforcement deadlines through 2025 for compounders to wind down shortage-based production
Because nausea, vomiting, constipation, and other digestive effects can occur, meal size and food choices may need to be adjusted with professional guidance
07 Right upper-quadrant abdominal pain Gallstone risk increases with rapid weight loss
doi:10.3389/fendo.2019.00551 Payne K, Lipshultz LI, Hotaling JM, Pastuszak AW